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To investigate the relationship between stem cells in normal epithelium and in squamous cell carcinomas (SCCs), we
examined expression of a panel of human epidermal stem cell markers in SCCs and SCC cell lines. Markers that are
co-expressed in normal stem cells were not co-expressed in SCC. Downregulation of two markers, Lrig1 and MAP4,
and upregulation of a third, MCSP, correlated with poor diﬀerentiation status and increased proliferation in primary
tumours. We conclude that SCCs do not reﬂect a simple expansion of stem cells; rather, tumour cells hijack the homeo-
static controls that operate in normal stem cells, eliminating those that maintain stem cell quiescence.
 2008 Elsevier Ireland Ltd.
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Stratiﬁed squamous epithelia act as a protective
interface between the body and the environment.
They have a simple organisation: proliferation takes
place in the basal layer of cells attached to an under-
lying basement membrane, and cells undergo termi-
nal diﬀerentiation as they move towards the tissue
surface [1]. The outermost cell layers are shed
throughout adult life and are replaced through pro-0304-3835  2008 Elsevier Ireland Ltd.
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Open access under CC BY licensliferation of a subpopulation of cells in the basal
layer known as stem cells [1]. Examples of stratiﬁed
squamous epithelia are the epidermis, the lining of
the oral cavity, the cervix and oesophagus.
One of the characteristic tumours of stratiﬁed
squamous epithelia is squamous cell carcinoma
(SCC). These tumours retain hallmarks of the nor-
mal epithelial terminal diﬀerentiation programme;
however, proliferation is increased, the proportion
of diﬀerentiated cells is decreased, and the spatial
organisation of the cell layers is disrupted [1]. There
is evidence that SCCs are maintained by a subpop-
ulation of proliferative cells termed cancer stem
cells, which are responsible for tumour maintenance
and for regrowth following conventional treatment
[2,3].e.
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between stem cells in normal stratiﬁed squamous
epithelia and stem cells in SCCs. However, it is gen-
erally believed that oncogenic changes in stem cells
are responsible for SCC development because stem
cells are the only long-lived cells within stratiﬁed
epithelia [1]. We recently generated single cell
cDNA libraries from normal human epidermal cells
and used them to identify a panel of 14 stem cell
markers [4]. In the present report, we have investi-
gated their expression in SCC, with a view to dis-
covering the relationship between stem cells in
normal stratiﬁed squamous epithelia and SCC.
2. Materials and methods
2.1. Cell culture conditions and stem cell fractionation
Primary human keratinocytes from neonatal
foreskin (strains kj, kt and kw), adult oral mucosa
(strain OK) and the SCC lines SCC9, SCC12B.2,
SCC13, SCC15, SCC25, SCC27 [5,6] and H376 [7]
were cultured in the presence of Mitomycin-C trea-
ted J2-3T3 feeder cells as described previously [8].
Stocks of A431 cells were cultured in DMEM sup-
plemented with 10% bovine serum, penicillin and
streptomycin. In clonal growth assays all cells,
including A431 cells, were cultured with a feeder
layer in the standard keratinocyte medium. For
RNA and protein isolation the medium of all cul-
tures was changed the day before analysis to fresh
standard keratinocyte medium.
Cell fractionation by rapid adhesion to 40 lg/ml
type I collagen was performed as described previ-
ously [4,9]. For cell sorting, cells were labelled with
Alexa 647 anti-human b1-integrin antibody (Sero-
tec), washed and subjected to ﬂow cytometry using
a Dako MoFlo high-speed cell sorter. Fractions of
100 cells were collected from the 10% of cells
expressing highest (b1high) and lowest (b1low) levels
of b1-integrin in addition to all b1-integrin positive
cells (All sort) and subjected to clonal analysis as
described previously [9].
2.2. Real-time PCR analysis
RNA was isolated from subconﬂuent cultures of
cells using Tri-reagent (Invitrogen) and cDNA was
generated as described previously [4]. Quantitative-
PCR was performed according to the manufac-
turer’s instructions. The list of genes examined is
described in Supplementary material.2.3. Immunostaining and antibodies
Human oral SCCs, normal oral mucosa and nor-
mal skin were obtained with appropriate ethical
approval. Frozen tissue sections were ﬁxed in 0.5%
paraformaldehyde for 5 min and permeabilised for
5 min with 0.4% Triton X-100. After blocking with
10% FCS in PBS, sections were incubated for 1 h
with antibodies diluted in 10% FCS in PBS. Cells
and sections were washed with 10% FCS in PBS
between incubations with primary and secondary
antibodies. Antibodies were used against the follow-
ing antigens: MCSP, MAP4 (9.2.27 and clone 18,
BD Life Sciences), Lrig1 (gift from Dr. Satoshi
Itami) and Ki67 (NCL-L-Ki67-MM1, Novocastra).
Secondary antibodies conjugated with Alexa Fluor
488 or 594 were obtained from Invitrogen.
Sections were mounted with Moviol and exam-
ined using a Zeiss 510 confocal microscope. For
quantitative measurements sections were examined
with a 20 objective using the Ariol system manu-
factured by Applied Imaging. This generated a
numerical value that reﬂected both staining inten-
sity and the proportion of tissue with detectable
staining.3. Results
3.1. Expression of stem cell markers in human squamous
cell carcinoma lines
We used real-time quantitative PCR (Q-PCR) to
examine gene expression levels of the 14 recently described
human epidermal stem cell markers in a panel of human
SCC cell lines. Five lines were derived from tumours of
the oral cavity (SCC9, SCC15, SCC25, SCC27 and
H376), two from facial epidermis (SCC12B.2 and
SCC13) and one from the vulva (A431). RNA was also
isolated from primary keratinocytes derived from normal
human epidermis or oral mucosa.
The SCC lines represented a range of ability to prolif-
erate and diﬀerentiate in culture (Fig. 1) [5–7,10]. All lines
except for SCC25 showed a 2- to 3-fold increase in colony
forming eﬃciency and expressed lower levels of the diﬀer-
entiation marker, involucrin, compared to epidermal and
oral keratinocytes (Fig. 1). Thus, by the criteria of
increased clonal growth ability and reduced involucrin
expression [9] the SCC lines appear to contain a higher
proportion of stem cells than primary keratinocytes.
We used Q-PCR to examine the expression of the 14
recently described human epidermal stem cell markers
[4]. Since most of the SCC lines were derived from the oral
cavity, we also compared marker expression in normal
oral and epidermal keratinocytes. Marker expression in
Fig. 1. Clonal growth and diﬀerentiation of human SCC lines. (A) Representative dishes of cells grown at clonal density and stained with
Rhodanile B are shown. (B) Quantitation of clonal growth was based on triplicate dishes in three independent experiments ± standard
deviation. (C) Analysis of Involucrin expression. Expression levels of Involucrin were determined by Q-PCR and normalised to expression
of 18S rRNA. Keratinocyte: epidermal keratinocytes.
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FRMD4A, an ERM domain-containing protein involved
in cytoskeleton rearrangement, which was expressed at
higher levels by oral keratinocytes (Fig. 2).
The markers could be assigned to three categories,
according to whether expression was decreased, increased,
or variable in SCC lines compared to normal epidermal
keratinocytes (Fig. 2). The two markers that were consis-
tently downregulated in the SCC lines were microtubule-
associated protein 4 (MAP4) and Leucine-rich repeats
and immunoglobulin-like domains 1 (Lrig1) (Fig. 2A).
MAP4 is reported to regulate cell cycle progression and
to be ubiquitously expressed in proliferating cells [11],
whereas Lrig1 is a negative regulator of the EGF receptor
and mediates epidermal stem cell quiescence [4,12,13].
The markers that were consistently upregulated in
SCC lines were: FRMD4A; oxidative stress response gene
1 (OSR1 or C20orf111); guanidine nucleotide binding
protein 1-like protein (GNL1 or HSR1), which is another
stress response gene; a serine kinase, phosphorylase bkinase (PYK), and FLJ12875, a regulator of the I-kappaB
kinase/NF-kappaB cascade. The upregulation was most
striking in the case of FRMD4A (Fig. 2B); however, since
expression was high in normal oral keratinocytes we con-
clude that elevated FRMD4A expression may reﬂect the
site of origin rather than the malignant status of the
cells.
The ﬁnal category of markers showed variable expres-
sion among the SCC lines (Fig. 2C). These were the puta-
tive ring ﬁnger protein KIAA1991; FAM120B, a protein
containing domains associated with DNA repair; Rnase5,
which is involved in mRNA degradation; the cell surface
proteoglycan MCSP; Additional Sex Combs-like 1 (Asxl-
1), which modulates polycomb and trithorax activity in
Drosophila; a putative transcription factor, zinc ﬁnger
protein 187 (Zfp187); and dimethyladenosine transferase
1-like (DIMT1L), which regulates ribosome activity. It
is worth noting that although MCSP is in the ‘variable’
category, it was upregulated in ﬁve out of seven primary
SCC lines from oral and facial epithelia.
Fig. 2. Analysis of levels of stem cell marker genes in by quantitative PCR. (A–C) Q-PCR of normal epidermal keratinocytes (Kera), oral
keratinocytes (Oral kera) and SCC lines. Expression levels of stem cell markers were normalised to expression of 18S rRNA. Genes were
assessed for statistically signiﬁcant diﬀerences against the panel of cell lines (unfractionated) and genes categorised as either down (A) or
up (B) regulated if the P-value was less than 0.01. (C) Genes with variable expression levels. Error bars represent the standard error of the
mean for at least triplicate samples.
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Human epidermal stem cells can be enriched by
selecting the basal cells that express the highest levels
of b1-integrins and adhere most rapidly to collagen [9].
The SCC lines examined express similar b1-integrin lev-
els to normal oral and epidermal keratinocytes [14,15].
We therefore investigated whether we could enrich for
clonogenic SCC cells on the basis of adhesiveness. In
the case of SCC9 and SCC12B.2, the 10% of cells with
the highest b1-integrin levels (b1high) had a signiﬁcantly
higher colony forming eﬃciency than all sorted cells
and the 10% of cells with the lowest levels (b1low) cells
(Fig. 3B and C). This was not observed for SCC27; how-
ever the colonies formed by b1high SCC27 cells were lar-ger than colonies formed by b1low cells (Fig. 3D). Thus,
as in normal epidermal keratinocytes, it is possible to
enrich for clonogenic SCCs on the basis of high b1-inte-
grin expression.
To investigate whether the observed expression pat-
terns in the SCC derived lines reﬂected variation within
the undiﬀerentiated, clonogenic cells, we performed Q-
PCR on cDNA generated from cells fractionated on the
basis of rapid adhesion to collagen, which reﬂects high
b1-integrin levels (Fig. 3; [9]). In SCC9, SCC12B.2 and
SCC27 cells and oral keratinocytes the relative levels of
marker expression when compared to epidermal keratino-
cytes were largely the same as in unfractionated cells
(Fig. 3E). FRMD4A was upregulated in oral keratino-
cytes and SCC cells compared to epidermal keratinocytes.
Fig. 3. Selection of clonogenic SCC cells. (A) Basal cells, gated on the basis of low forward and side scatter [9] were labelled with anti-b1-
integrin antibody. The 10% of cells with highest (b1-integrin high) and lowest (b1-integrin low) integrin levels were sorted and plated out at
clonal density. (B) Representative dishes of cells from the clonogenicity assay, stained with Rhodanile B. (C) Colony forming eﬃciency was
determined as % plated cells that formed colonies. ±SEM of triplicate samples. Asterisks indicate signiﬁcant diﬀerences (p < 0.05, two-way
unpaired T-test). (D) Relative colony size was measured using Image J, and the mean was determined for all colonies ± SEM. Asterisks
indicate signiﬁcant diﬀerences (p < 0.05, two tailed Mann–Whitney test of the median). (E) Q-PCR forMCSP,MAP4, Lrig1 and Frmd4a
in populations of normal oral and epidermal keratinocytes and a subset of SCC lines enriched for stem cells by rapid adhesion to collagen.
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MCSP expression was variable, expression being lowest
in SCC12B.2 and highest in SCC27, reﬂecting the changes
observed in unfractionated cells. However, whereas
reduced Lrig1 expression was a consistent characteristic
of unfractionated cells (Fig. 2A), the levels of Lrig1 were
remarkably similar in the enriched populations (Fig. 3D).
Thus, clonogenic cells in SCC lines and primary keratino-
cytes express similar levels of Lrig1. The decrease in Lrig1expression that characterises SCC lines may therefore be
associated with expansion of the transit amplifying
compartment.
3.3. Studies in primary tumours
The data from the SCC lines make two predictions
about marker expression in primary tumours: that mark-
ers that are co-expressed in the basal layer of normal epi-
Table 1
A panel of selected genes known to be either involved in tumour
progression and/or SC maintenance in normal tissue
Gene name Entries Signal P-value
CD44 3 Up 6.70E14
MCSP 1 Up 2.50E04
MAP4 1 Down 5.10E06
LRIG1 2 Down 2.60E05
The data are derived from expression proﬁling of 31 oral squa-
mous cell carcinomas and 26 samples of normal oral epithelium
[17]. The gene name is listed in column 1, the number of diﬀerent
probes detecting the gene is indicated in column 2, whether the
gene is up or downregulated is listed in column 3 and the P-value
for the ﬁnding is listed in column 4.
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lation of MAP4 and Lrig1 is a characteristic feature of
SCCs. Support for the second prediction came from anal-
ysis of a publicly available gene data set deposited at
Oncomine [16,17]. We found that MAP4 and Lrig1 were
signiﬁcantly downregulated in oral SCCs, while CD44,
which has recently been reported to be a marker of
tumour initiating cells in head and neck SCCs [3], and
MCSP were highly upregulated (Table 1).
To examine the sites of marker expression, we stained
sections of 18 human oral SCCs, one adenoid cystic carci-
noma, one lymph node metastasis of an oral SCC and two
specimens of normal skin, as well as four samples of nor-Fig. 4. Expression of stem cell markers in human epidermis and squam
(green), (E–H) MAP4 (red) and Ki67 (green) in epidermis (normal) an
(well, moderate, poor). Location of putative stem clusters is marked
inserts. Scale bars: 200 lm.mal oral mucosa. We evaluated proliferative status by
Ki67 labelling and graded the diﬀerentiation status of
the tumours according to standard criteria [18] (Table 2).
Expression levels in normal and tumour tissue were
scored by eye as negative (/+), weak (+), moderate
(++) or strong (+++), based on the intensity and extent
of staining (Table 2). We conﬁrmed our scoring for Lrig1
expression on one sample of normal skin and ﬁve
tumours, picked at random using an Applied Imaging
Ariol system. The results were as follows (visual score
in brackets): normal epidermis, 78 ± 3 (+++); tumour
W3, 49 ± 6 (++); tumour P3, 21 ± 3 (+/); tumour
M4, 32 ± 12 (+); tumour M7, 33 ± 10 (+/); tumour
MET1, 17 ± 7 (). There was thus good agreement
between the visual and automated scores.
As reported previously [4], in normal epidermis Lrig1
and MCSP were expressed most abundantly in clusters
of putative stem cells in the basal layer (brackets in
Fig. 4A). MAP4 was expressed throughout the epidermal
basal layer, expression being highest in the stem cell clus-
ters (brackets in Fig. 4E). Thus, in normal epidermis
Lrig1, MCSP and MAP4 were co-expressed, expression
being highest in the putative SC clusters that are known
to be less frequently dividing than other cells in the basal
layer [19,20].
As predicted, expression of Lrig1 and MAP4 was
markedly decreased in tumours (Fig. 4B–D, F–H and
Table 2). The number of cells expressing Lrig1 was
reduced, as was the labelling intensity (Fig. 4B–D). Inous cell carcinomas. Expression of (A–D) MCSP (red) and Lrig1
d in squamous cell carcinomas of diﬀering diﬀerentiation status
with horizontal lines. Panels A, E contain higher magniﬁcation
Table 2
Expression pattern of selected proteins in human primary SCCs as determined by indirect immunoﬂuorescence
Tumour Lrig1 MCSP MAP4 Diﬀerentiation Tissue
Foreskin +++ + +++
Oral mucosa ++ + +++
P1 + ++ +/++ Poor Lateral border of tongue
P2 + ++ + Poor Tongue
P3 /+ +++ + Poor Maxillary antrum
P4 +/++ +++ ++/ +++ Poor Buccal mucosa
P5  + +/++ Poor Right tonsil
MP1 ++ ++ ++ Mod/poor Dorsum tongue
M1 + ++ + Moderate Lateral border of tongue
M2 + ++ + Moderate Retromolar
M3 ++ ++ ++ Moderate Lateral border of tongue
M4 + +++ +/++ Moderate Lateral border of tongue
M5 + ++ +/ Moderate Alveolar ridge maxilla
M6 + ++ + Moderate Buccal mucosa
M7 /+ +++ + Moderate Buccal mucosa
M8 ++ +++ + Moderate Lateral tongue
W1 ++ ++ + Well Lateral border of tongue
W2 ++ +++ +/++ Well Buccal mucosa
W3 ++ ++ + Well Ventral tongue
W4 ++ ++ + Well Floor of mouth
ACC1 — +++ /+ Adenoid cystic carcinoma Sublingual gland
MET1 — ++ — Poor Submandibular lymph node
Summary
Poor Down Up Down
Moderate Down Up Down
Well NGC Up Down
Staining intensity was scored by eye as negative (/+), weak (+), moderate (++) or strong (+++), based on the intensity and extent of
staining. NGC: no general change.
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intensity, irrespective of diﬀerentiation status (Fig. 4F–H).
Moreover, low levels of MAP4 expression extended
throughout the tumour mass, whereas in normal epider-
mis expression was conﬁned to the basal layer.
There was a tight correlation between expression of
Lrig1 and the degree of tumour diﬀerentiation, as
reported previously [21]. Lrig1 was detected in well and
moderately diﬀerentiated tumours but was markedly
reduced in poorly diﬀerentiated tumours (Fig. 4B–D). In
4/5 poorly diﬀerentiated tumours Lrig1 was either unde-
tectable () or expressed in only occasional cells (/+
or +). In one tumour most areas had only a few positive
cells (+), although there was one region with more exten-
sive staining (++). Ki67 positive cells did not express
Lrig1, consistent with its role as a negative regulator of
proliferation (data not shown). In well and moderately
diﬀerentiated tumours Lrig1 was detected in the supraba-
sal layers, correlating with areas that were Ki67 negative
and consistent with Lrig1 expression in normal oral
mucosa (data not shown, Table 2).
While Lrig1 and MAP4 expression was decreased in
tumours, MCSP expression was upregulated (Table 2;
Fig. 4B–D). In well and moderately diﬀerentiated tumours
MCSP expression was largely conﬁned to the epithelial
layer adjacent to the tumour stroma (Fig. 4B and C). Inpoorly diﬀerentiated tumours MCSP was expressed
throughout the tumour (Fig. 4D). Whereas Lrig1 and
MCSP are co-expressed in the basal layer of normal epi-
dermis ([4]; Fig. 4A), MCSP positive cells in tumours
lacked Lrig1 expression (Fig. 4B–D).4. Discussion
The panel of markers that were co-expressed in
keratinocytes from normal human epidermis [4]
were, with the exception of FRMD4A, expressed
at similar levels in keratinocyte from normal oral
mucosa. Furthermore, we could enrich for clono-
genic, putative stem cells on the basis of high b1-
integrin expression and rapid adhesion to collagen
in normal epidermal and oral keratinocytes, and in
some of the SCC lines examined. While we did not
examine inter-clonal diﬀerences within the SCC
lines [2], the overall increase in colony forming eﬃ-
ciency and decrease in involucrin expression would
indicate an expansion of the stem cell compartment.
Nevertheless, these features did not correlate with
increased expression of the entire panel of stem cell
markers. Instead, while some markers were upregu-
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showed variable changes amongst the diﬀerent
SCC lines. In addition, basal cells in SCCs did not
maintain the full complement of markers normally
observed in the basal layer of oral and epidermal
epithelium. Thus, there is no evidence for expansion
of the normal stem cell compartment in SCCs.
Downregulation of MAP4 and Lrig1 and upreg-
ulation of MCSP were consistent features of SCC
lines and primary tumours. Lrig1 is known to nega-
tively regulate EGFR signalling, thereby maintain-
ing epidermal stem cells in a quiescent,
nondividing state [4,21]. It is likely that loss of Lrig1
in SCCs, which is associated with a poor prognosis
[21,22], will confer a signiﬁcant growth advantage in
the basal layer, and lead to an expansion of commit-
ted progenitors via upregulation of EGFR signal-
ling. Just as loss of Lrig1 will impact on a variety
of signalling pathways, so will upregulation of
MCSP. MCSP activates the small GTPases
CDC42 and Rac1 via an integrin-mediated pathway
[23,24]. This is intriguing as we previously reported
increased expression of the small GTPase Rac1 in
SCCs as well as the tumour promoting role of
altered epidermal integrin expression [25,26]. Less
is known about the likely consequences of loss of
MAP4 in SCCs. MAP4 undergoes extensive post-
translational modiﬁcations and interacts with a
number of diﬀerent proteins that regulate cell cycle
progression and cytokinesis [11]. We speculate that
reduced levels of MAP4 in SCCs facilitate more
rapid cell cycle progression; however, this remains
to be tested.
We have demonstrated the existence of cellular
heterogeneity in SCC lines, based on the expression
of b1 integrins and ability to adhere to extracellular
matrix components. In three out of four genes ana-
lysed, diﬀerences in expression observed in the clo-
nogenic cell-enriched fraction reﬂected diﬀerences
in the total cell population. The notable exception
was Lrig1. While Lrig1 was consistently downregu-
lated in unfractionated SCC lines and primary
tumours, the levels of Lrig1 in the stem cell-enriched
fractions were remarkably similar to normal oral
and epidermal stem cells. This suggests that there
is a subpopulation of SCC cells that are subject to
negative regulation of EGFR signalling. Their exis-
tence is important clinically, because these cells will
be less likely to respond to drugs that target cells
with elevated EGFR signalling and may be capable
of reinitiating tumour growth following therapy. In
addition, it will be important to determine whethertumour initiation is a general feature of basal cells
with high b1-integrin levels, or whether a combina-
tion of markers such as CD44, MCSP and Lrig1 will
allow further enrichment.
In conclusion, our data favour a model whereby
during tumour development the pathways that con-
trol epithelial homeostasis are lost, particularly in
the basal cell layer closest to the tumour stroma.
Those markers of normal stem cells that exert a
positive eﬀect on proliferation or inhibit diﬀerentia-
tion are upregulated, while those that normally
retain the cells in a nondividing state show reduced
expression. As we ﬁnd out more about how diﬀerent
signalling pathways intersect to maintain homeosta-
sis we will have more opportunities for restoring
homeostasis in tumours.
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